Welireg (belzutifan tablets - Merck) — Cigna

Initial criteria

• Patient is age ≥ 18 years; AND
• Patient has advanced disease; AND
• The cancer has a clear cell histology; AND
• Patient has tried at least one programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor; AND
• Patient has tried at least one vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)

Approval duration

1 year